Mozavaptan (hydrochloride) (Standard)

Mozavaptan (hydrochloride) (Standard) is the analytical standard of Mozavaptan (hydrochloride) . This product is intended for research and analytical applications. Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment[1][2].

Product Specifications

CAS Number

[138470-70-9]

UNSPSC

12352100

Target

Reference Standards; Vasopressin Receptor

Related Pathways

GPCR/G Protein; Others

Field of Research

Cancer; Endocrinology; Metabolic Disease; Cardiovascular Disease

Smiles

CC1=CC=CC=C1C(NC2=CC=C(C(N3C(C=CC=C4)=C4C(N(C)C)CCC3)=O)C=C2)=O.Cl

Molecular Formula

C27H30ClN3O2

Molecular Weight

464.00

References & Citations

[1]Yamamura Y, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992 Apr;105 (4) :787-91.|[2]Yamaguchi K, et al. Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome. Jpn J Clin Oncol. 2011 Jan;41 (1) :148-52.